The biopharma industry went through a year of transition in 2023. Companies faced challenges, from difficult public financing markets, to venture capitalists who now, more than ever, are more selective with investments, to increased regulatory scrutiny of merger and acquisition (M&A) activity. Pharma is also adjusting deal-making strategies following the passage of the US Inflation Reduction Act.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD